Radiotherapy in patients with connective tissue diseases

详细信息    查看全文

• 作者：Dr Niccolò ; Giaj-Levra ; MD^a ; ^{niccolo.giajlevra@sacrocuore.it" class="auth_mail" title="E-mail the corresponding author} ; Savino Sciascia ; PhD^b ; Alba Fiorentino ; MD^a ; Sergio Fersino ; MD^a ; Rosario Mazzola ; MD^a ; Francesco Ricchetti ; MD^a ; Prof Dario Roccatello ; MD^b ; Filippo Alongi ; MD^a
• 刊名：The Lancet Oncology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：17
• 期：3
• 页码：e109-e117
• 全文大小：461 K

文摘

The decision to offer radiotherapy in patients with connective tissue diseases continues to be challenging. Radiotherapy might trigger the onset of connective tissue diseases by increasing the expression of self-antigens, diminishing regulatory T-cell activity, and activating effectors of innate immunity (dendritic cells) through Toll-like receptor-dependent mechanisms, all of which could potentially lead to breaks of immune tolerance. This potential risk has raised some debate among radiation oncologists about whether patients with connective tissue diseases can tolerate radiation as well as people without connective tissue diseases. Because the number of patients with cancer and connective tissue diseases needing radiotherapy will probably increase due to improvements in medical treatment and longer life expectancy, the issue of interactions between radiotherapy and connective tissue diseases needs to be clearer. In this Review, we discuss available data and evidence for patients with connective tissue diseases treated with radiotherapy.